Foghorn therapeutics announces upcoming investor conference participation

Cambridge, mass., may 31, 2022 (globe newswire) -- foghorn® therapeutics inc. (nasdaq: fhtx), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced management's participation in the following investor conferences. with an initial focus in oncology, foghorn's gene traffic control® platform and resulting broad pipeline has the potential to transform the lives of people suffering from a wide spectrum of diseases.
FHTX Ratings Summary
FHTX Quant Ranking